Camurus AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CAMRF research report →
Companywww.camurus.com
Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence; episil oral liquid, a medical device for the treatment of inflammatory and painful conditions in the oral cavity; and Brixadi to treat opioid use disorder Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; CAM2047 for the treatment of chemotherapy-induced nausea and vomiting that is in phase 1 clinical trial; and CAM2048, which is in phase I clinical trial for postoperative pain.
- CEO
- Fredrik Tiberg
- IPO
- 2017
- Employees
- 238
- HQ
- Lund, SE
Price Chart
Valuation
- Market Cap
- $3.77B
- P/E
- 46.70
- P/S
- 14.24
- P/B
- 7.20
- EV/EBITDA
- 31.59
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 92.53%
- Op Margin
- 36.74%
- Net Margin
- 30.45%
- ROE
- 16.39%
- ROIC
- 14.20%
Growth & Income
- Revenue
- $2.27B · 21.30%
- Net Income
- $735.57M · 71.70%
- EPS
- $12.42 · 68.06%
- Op Income
- $873.93M
- FCF YoY
- 103.78%
Performance & Tape
- 52W High
- $71.07
- 52W Low
- $52.31
- 50D MA
- $58.82
- 200D MA
- $64.62
- Beta
- 1.09
- Avg Volume
- 5
Get TickerSpark's AI analysis on CAMRF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our CAMRF Coverage
We haven't published any research on CAMRF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CAMRF Report →